Topical Dapsone 5% Gel + oral antibiotics
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Cetuximab-induced Papulopustular (Acneiform) Rash Who Have
Conditions
Cetuximab-induced Papulopustular (Acneiform) Rash Who Have, Metastatic Colorectal Cancer or Head and Neck Squamous Cell Carcinoma
Trial Timeline
Aug 1, 2013 → Sep 1, 2015
NCT ID
NCT01931150About Topical Dapsone 5% Gel + oral antibiotics
Topical Dapsone 5% Gel + oral antibiotics is a phase 3 stage product being developed by Bristol Myers Squibb for Cetuximab-induced Papulopustular (Acneiform) Rash Who Have. The current trial status is completed. This product is registered under clinical trial identifier NCT01931150. Target conditions include Cetuximab-induced Papulopustular (Acneiform) Rash Who Have, Metastatic Colorectal Cancer or Head and Neck Squamous Cell Carcinoma.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01931150 | Phase 3 | Completed |